A New “Brew” of MALT1 Inhibitors
Authors:
- Louis M. StaudtLSLouis M. Staudt
- 1 December 2012
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 22 (6) , 706-707
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In VivoCancer Cell, 2012
- Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCLCancer Cell, 2012
- Congenital B cell lymphocytosis explained by novel germline CARD11 mutationsJournal of Experimental Medicine, 2012
- MALT1 Protease: A New Therapeutic Target in B Lymphoma and Beyond?Clinical Cancer Research, 2011
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphomaProceedings of the National Academy of Sciences, 2009
- Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cellsJournal of Experimental Medicine, 2009
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell LymphomaScience, 2008
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006